Oral contraceptives and hypertension

Hypertension

Volumn 11, Issue 3, 1988, Pages II.11-II.15

  Woods, James W ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Blood pressure; Estrogen; Experimental models; Mechanisms; Oral contraceptive; Progestogen

Indexed keywords

ESTROGEN; GESTAGEN; ORAL CONTRACEPTIVE AGENT;

BLOOD PRESSURE; EXPERIMENTAL MODEL; HUMAN; HYPERTENSION; PRIORITY JOURNAL; SHORT SURVEY;

ANIMAL; CARDIOVASCULAR DISEASES; CONTRACEPTIVES, ORAL, HORMONAL; ESTROGENS; FEMALE; HUMAN; HYPERTENSION; PROGESTATIONAL HORMONES; RATS; RISK FACTORS;

EID: 1842311073     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/01.hyp.11.3_pt_2.ii11     Document Type: Article

References (27)

1. Woods JW. Oral contraceptives and hypertension. Lancet 1967;2:653-654
2. Laragh JH, Sealey JE, Ledingham JGG, Newton MA. Oral contraceptives. Renin, aldosterone, and high blood pressure. JAMA 1967;201:918-922
3. Tyson JEA. Oral contraception and elevated blood pressure. Am J Obstet Gynecol 1968;100:875-876
4. Saruta T, Saade GA, Kaplan NM. A possible mechanism for hypertension induced by oral contraceptives. Arch Intern Med 1970; 126:621-626
5. Weir RJ, Briggs E, Mack A, Naismith L, Taylor L, Wilson E. Blood pressure in women taking oral contraceptives. Br Med J 1974;1:533-535
6. Clezy TM, Foy BN, Hodge RL, Lumbers ER. Oral contraceptives and hypertension. An epidemiological survey. Br Heart J 1972;34:1238-1243
7. Report of the Royal College of General Practitioners. Hypertensio. In: Oral contraceptives and health. London: Pitmann
8. Vessey MP, McPherson K, Johnson B. Mortality among women participating in the Oxford University Family Planning Association Contraceptive Study. Lancet 1974;2:731-733
9. Ramcharan S, Pellegrin FA, Hoag EJ. The occurrence and course of hypertensive disease in users and nonusers of oral contraceptive drugs. In: Ramcharan S, ed. The Walnut Creek Contraceptive Drug Study: a prospective study of the side effects of oral contraceptives, vol 2. US Department of Health, Education, and Welfare publication no. (NIH)76-563. Washington, DC: Government Printing Office 1976;1-16
10. Stem MP, Brown BW Jr, Haskell WL, Farquhar JW, Wehrle CL, Woods PDS. Cardiovascular risk and use of estrogens or estrogen-progestogen combinations. Stanford Three-Community Study. JAMA 1976;235:811-815
11. Blumenstein BA, Douglas MB, Hall WD. Blood pressure changes and oral contraceptive use: a study of 2676 black women in the southeastern United States. Am J Epidemiol 1980;112:539-552
12. Khaw K, Peart WS. Blood pressure and contraceptive use. Br Med J 1982;285:402-407
13. Layde PM, Beral V, Kay CR. Further analyses of mortality in oral contraceptive users. Royal College of General Practitioners Oral Contraception Study. Lancet 1981;1:541-546
14. Stadel BV. Oral contraceptives and cardiovascular disease. N Engl J Med 1981;305:612-618, 672-677
15. Royal College of General Practitioners Oral Contraceptive Study. Effect on hypertension and benign breast disease of progestogen component in combined oral contraceptives. Lancet 1977; 1:624
16. Spellacy WN, Birk SA. The effect of intrauterine devices, oral contraceptives, estrogens, and progestogens on blood pressure. Am J Obstet Gynecol 1972;112:912-919
17. Weir RJ. Effect on blood pressure of changing from high to low dose steroid preparations in women with oral contraceptive induced hypertension. Scott Med J 1982;27:212-215
18. Briggs M, Briggs M. Oestrogen content of oral contraceptives [Utter]. Lancet 1977;2:1233
19. HelmerOM, Griffith RS. Effect of the administration of estrogens on the renin-substrate (hypertensinogen) content of rat plasma. Endocrinology 1952;51:421-426
20. Origara T, Hata T, Maruyama A, Nakamaru M, Mikami H, Kumahara V. Effects of an angiotensin II antagonist on blood pressure, plasma-renin activity and plasma aldosterone concentration in hypertensive and normotensive subjects taking oral contraceptives. Endccrinol Jpn 1979;26:591-597
21. Fowler WL Jr, Johnson JA, Kurz KD, Payne CG. Reninangiotensin mechanisms in oral contraceptive hypertension in conscious rats. Am J Physiol 1985;248:H695-H699
22. McAreavey D, Cummings AM, Boddy K, et al. The reninangiotensin system and total body sodium and potassium in hypertensive women taking oestrogen-progestogen oral contraceptives. Clin Endocrinol 1983;18:111-118
23. Aitken JM, Lindsay R, Hart DM. The redistribution of body sodium in women on long-term oestrogen therapy. Clin Soi Mol Med 1974;47;179-187
24. Weder AB. Red-cell lithium-sodium countertransport and renal lithium clearance in hypertension. N Engl J Med 1986314:198-201
25. Boyd WN, Burden RP, Aber GM. Intrarenal vascular changes in patients receiving oestrogen-containing compounds - a clinical, histological and angiographic study. Q J Med N S 1975;44:415-431
26. Fregly MI. Effects of chronic administration of an oral contraceptive on the blood pressure of rats. Toxicol Appl Pharmacol 1973;25:560-568
27. Stubbs DH, Johnson JA, Ichikawa S, Fowler WL Jr, Kilfoil J, Keitzer WF. Role of angiotensin II in oral contraceptive hypertension in anesthetized rats. Life Sci 1980;27:435-440